Cynosure Group LLC Has $382,000 Stock Position in Danaher Corporation (NYSE:DHR)

Key Points

• Cynosure Group LLC reduced its holdings in Danaher Corporation by 80.4% during the first quarter, selling 7,647 shares and ending up with 1,865 shares valued at approximately $382,000.
• Several analysts have recently rated Danaher, with price targets ranging from $225.00 to $250.00, and the stock has an average rating of "Moderate Buy".
• Danaher reported quarterly earnings of $1.80 per share, exceeding analysts' expectations, and generated revenue of $5.94 billion, up 3.4% from the same quarter last year.

Cynosure Group LLC lessened its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 80.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,865 shares of the conglomerate's stock after selling 7,647 shares during the period. Cynosure Group LLC's holdings in Danaher were worth $382,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of DHR. Vanguard Group Inc. boosted its position in Danaher by 0.4% during the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock valued at $12,296,123,000 after purchasing an additional 230,966 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Danaher by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock valued at $1,800,614,000 after purchasing an additional 194,466 shares during the last quarter. Northern Trust Corp boosted its position in Danaher by 14.3% during the fourth quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate's stock valued at $1,821,477,000 after purchasing an additional 992,594 shares during the last quarter. Capital World Investors boosted its position in Danaher by 32.7% during the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock valued at $1,460,215,000 after purchasing an additional 1,566,658 shares during the last quarter. Finally, Capital Research Global Investors boosted its position in Danaher by 6.8% during the fourth quarter. Capital Research Global Investors now owns 5,812,728 shares of the conglomerate's stock valued at $1,334,312,000 after purchasing an additional 370,111 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Wall Street Analyst Weigh In

DHR has been the subject of a number of research reports. Jefferies Financial Group reduced their price objective on Danaher from $260.00 to $230.00 and set a "buy" rating for the company in a research report on Tuesday, April 22nd. Deutsche Bank Aktiengesellschaft dropped their price objective on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Robert W. Baird lifted their price objective on Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research note on Friday, July 18th. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Finally, Royal Bank Of Canada reiterated an "outperform" rating and issued a $250.00 price objective on shares of Danaher in a research note on Wednesday, April 23rd. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $247.61.

Danaher Stock Up 1.7%

Shares of NYSE DHR traded up $3.56 during mid-day trading on Wednesday, hitting $209.28. The company had a trading volume of 3,241,247 shares, compared to its average volume of 4,263,512. The company has a market capitalization of $149.86 billion, a PE ratio of 44.53, a price-to-earnings-growth ratio of 2.79 and a beta of 0.73. The firm has a 50-day simple moving average of $198.95 and a two-hundred day simple moving average of $200.34. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. Danaher Corporation has a one year low of $171.00 and a one year high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The company had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same quarter last year, the company earned $1.72 EPS. Danaher's revenue for the quarter was up 3.4% compared to the same quarter last year. On average, equities analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.